Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

www.MarketResearchReports.com

OpportunityAnalyzer: Graft-Versus-Host

Disease - Opportunity Analysis and

Forecasts to 2018

Category : Pharma & Healthcare

All logos and Images mentioned on this slide belong to their respective owners.

http://www.marketresearchreports.com/


Introduction to Report

Launch Date: August 20, 2014

Number of Pages: 252

Geography Coverage: Global

Available Format: PDF

Price For Single User License: USD 5,995

Price For Site User License: USD 11,990

Price For Global User License: USD 17,985

Delivery Time: Within 24 Hours (During Working Days)



About the Report

The main drivers of growth in graft versus host disease over the 2013-2018 forecast period include the increasing numbers of allogeneic hematopoietic stem cell transplants and the increasing use of biologic off-label and marketed therapies in the 6MM.

Sanofi is a key player in the GVHD market with Thymoglobuline and Lemtrada by infiltrating prophylaxis, aGVHD and cGVHD. Gaining more and more ground in the treatment management of cGVHD is Roche’s Rituxan that Publisher estimates will be one of the bestselling biologics in GVHD in the US by 2018.



Research Finding

The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research.

"OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018" report states that this growth, which will occur over six major markets (6MM: the US, France, Germany, Italy, Spain and the UK), will be strongest in the five European countries (5EU), where multiple product launches will accelerate the market value at a CAGR of 9.26% during the forecast period.

Several products are due to enter the GVHD market by 2018, with Osiris Therapeutics and Mesoblast’s first-to-market Prochymal expected to generate sales of $12.2 million in 2018.



Key Findings

High uptake of off-label biologics (Rituxan, Lemtrada, Remicade and Thymoglobuline)

No national guidelines are in place

GVHD remains a field of highly unattained unmet need

No consensus over clinical trial endpoints

Regulatory T cells (Tregs) are the focus of the early stage pipeline

Huge opportunity exists in the chronic patient segment of GVHD

Institutionally funded studies are the core of GVHD treatment management



Report Coverage

1. Introduction

2. Disease Overview

3. Epidemiology

4. Current Treatment Options

5. Unmet Need and Opportunity

6. Research and Development Strategies

7. Pipeline Assessment

8. Pipeline and Off-Label Valuation Analysis

9. Appendix



Custom Research: Are you an industry professional, entrepreneur,

venture capitalist, investors and organization, then let us know your specific research requirements. Our goal is to cater to your requirements be it for a custom market research project, syndicated research report on a specific market or industry sector, newsletter creation, case study development or anything else related to marketing research.

For Any Customization Related query Visit IdeaCenter @http://www.marketresearchreports.com/idea-center

http://www.marketresearchreports.com/idea-center



How To Buy This Report?

Visit following URL to see Table of Content and purchase this publication:

http://mrr.cm/ZXd

About Market Research Reports, Inc.Market Research Reports provides a customized set of reports from reputed Publishers, built on the intelligence available within organizations and leverages on our motto of “Intelligence Redefined”.

Contact : Amitava SenEmail : [email protected]: +1 302-703-7787 (USA) +91-8762746600 (India)

http://mrr.cm/ZXd

http://mrr.cm/ZXd

mailto:[email protected]


Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018

Healthcare

Transcript of Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018